DEEP Study to Evaluate Safety and Effectiveness of Minimally-Invasive Atrial Fibrillation Treatment
You may qualify for this minimally-invasive afib treatment study
April 26, 2016
- Summary: The DEEP study will evaluate the safety and effectiveness of a minimally-invasive treatment for patients with atrial fibrillation.
- Reading time: 1–2 minutes
The DEEP (Dual Epicardial and Endocardial Procedure) research study is designed to establish a safe and reliable minimally-invasive treatment for atrial fibrillation.
It involves a cardiac surgeon and an electrophysiologist working together.
The cardiac surgeon first performs a minimally-invasive surgical ablation on the outside of the heart (epicardial), and in a follow-on procedure approximately 90 days later, the electrophysiologist performs a catheter ablation on the inside of the heart (endocardial).
The desired outcome of the DEEP research study is to provide freedom from atrial fibrillation, atrial flutter, and atrial tachycardia over a 12-month follow-up period without patients being on rhythm control (antiarrhythmic) drugs.
You may qualify to participate in this study if you have been diagnosed with atrial fibrillation. If you qualify, your medical care will be provided by board-certified physicians and hospitals that specialize in afib treatment. Patients may also receive compensation for participating in this study.
Who May Qualify?
You may be eligible for this afib study if:
- You are between 18-75 years of age
- You have experienced afib symptoms for longer than 48 hours
- You have taken common rhythm control (antiarrhythmic) drugs
To learn more about the study, including who is eligible and what centers are participating, see: